denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: the Multiple Myeloma Research Foundation
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
CRS, neurotoxicity, bioengineering, Therapies, Combinations, Adverse Events, Technology and Procedures, cytogenetics, genetic profiling, Clinically relevant, imaging, flow cytometry, NGS
Hematology Disease Topics & Pathways:
CRS, neurotoxicity, bioengineering, Therapies, Combinations, Adverse Events, Technology and Procedures, cytogenetics, genetic profiling, Clinically relevant, imaging, flow cytometry, NGS
Friday, December 4, 2020: 7:00 AM-10:00 AM
Chairs:
Hearn Jay Cho, MD, PhD, Multiple Myeloma Research Foundation, Icahn School of Medicine at Mount Sinai
,
Paul G. Richardson, MD, Dana-Farber Cancer Institute
and
A. Keith Stewart, MBChB, Princess Margaret Cancer Centre, University Health Network
Disclosures:
Richardson: Celgene/BMS, Oncopeptides, Takeda, Karyopharm: Research Funding. Stewart: Amgen, Bristol-Myers Squibb, Celgene, Ionis, Janssen, Oncopeptides, Ono, Roche, Seattle Genetics, Takeda: Other; Amgen, Celgene, Janssen: Other.
Speakers:
Adam D. Cohen, MD, Perelman School of Medicine at the University of Pennsylvania
,
Suzanne Lentzsch, MD, PhD, Columbia University Medical Center
and
David S. Siegel, MD, Hackensack Univ. Med. Ctr.
Disclosures:
Cohen: Novartis: Other: Patents/Intellectual property licensed, Research Funding; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda,: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Membership on an entity's Board of Directors or advisory committees. Lentzsch: Mesoblast: Divested equity in a private or publicly-traded company in the past 24 months; Janssen: Consultancy; Caelum Biosciences: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Celularity: Consultancy, Other; Magenta: Current equity holder in private company; Karyopharm: Research Funding. Siegel: Janssen: Consultancy, Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria, Speakers Bureau; Karyopharma: Consultancy, Honoraria; Merck: Consultancy, Honoraria, Speakers Bureau; Celulatiry: Consultancy.
In the last 17 years, clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. Perhaps even more remarkably, in this time 14 new drugs have been approved by the US Food and Drug Administration for use in MM—including eight new agents (panobinostat, ixazomib, elotuzumab, daratumumab, denosumab, selinexor, isatuximab, belantamab mafodotin) approved in the last 5 years alone. This expansion of treatment options brings both opportunities and challenges for oncology health care providers (HCPs). Indeed, the rapidity with which research data relating to MM diagnosis, monitoring, and therapy has matured and emerged to practice relevance ensures that MM management options will continue to expand and evolve.
This symposium will follow a debate format and feature audience polling relating to the proffered arguments, as well as panel discussions.
See more of: Satellite Symposia